Tags: oncology, EU approval, ADC, Padcev, Trodelvy, market access

Padcev and Trodelvy notch new EU oncology wins that field teams will have to answer for

By FieldPulse Editorial · June 24, 2026

Padcev and Trodelvy both picked up new EU approvals, giving oncology field teams fresh competitive and access signals across bladder and breast cancer.

Europe handed oncology teams two meaningful commercial signals on the same day.

According to pharmaphorum, Astellas' Padcev and Gilead's Trodelvy both secured new EU approvals, expanding the set of account conversations that bladder cancer and breast cancer field teams will be expected to navigate.

The Padcev update matters because it strengthens an already important franchise around enfortumab vedotin in bladder cancer.

Hermes flagged that the approval reaches across additional perioperative and earlier-use settings tied to the Padcev-Keytruda combination.

For field teams connected to Astellas, Pfizer, Seagen, and Merck, that means the EU story is no longer just about defending a single established use.

It becomes a broader discussion about where the regimen now fits across the treatment pathway and how quickly European stakeholders may begin recalibrating expectations.

That has practical implications even for teams that do not directly sell in Europe.

Global approvals often shape how internal leadership talks about momentum, how competitive teams prepare response materials, and how account-facing teams think about the durability of an oncology franchise.

When a combination gains more room to operate in earlier or perioperative settings, competitors have to assume that the standard of discussion is rising, even before local commercial effects are fully realized in every market.

Trodelvy's EU approval matters for a different but equally relevant reason.

Gilead now has another visible access milestone in triple-negative breast cancer, a category where treatment sequencing, differentiation, and physician familiarity all influence how a field narrative holds up.

A new regulatory win does not automatically solve every reimbursement or uptake question, but it does give Gilead teams a firmer proof point when discussing the brand's place in the treatment landscape.

For competing oncology teams, the bigger takeaway is that the ADC bar keeps moving.

The category is no longer.